|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 76.55 EUR | -1.54% |
|
+1.73% | -18.92% |
| 08:01am | GERRESHEIMER AG : JP Morgan remains its Buy rating | ZD |
| Dec. 03 | GERRESHEIMER AG : JP Morgan keeps its Buy rating | ZD |
| Capitalization | 2.69B 2.82B 2.49B 2.21B 4B 239B 4.43B 30.99B 11.44B 98.32B 10.59B 10.36B 429B | P/E ratio 2024 * |
21.1x | P/E ratio 2025 * | 16x |
|---|---|---|---|---|---|
| Enterprise value | 3.69B 3.88B 3.42B 3.04B 5.49B 329B 6.09B 42.61B 15.73B 135B 14.56B 14.25B 590B | EV / Sales 2024 * |
1.8x | EV / Sales 2025 * | 1.57x |
| Free-Float |
96.72% | Yield 2024 * |
1.64% | Yield 2025 * | 1.88% |
More valuation ratios
* Estimated data
More news
Last Transcript: Gerresheimer AG
More recommendations
More press releases
More news
| 1 day | -0.19% | ||
| 1 week | +2.57% | ||
| Current month | +4.08% | ||
| 1 month | +2.71% | ||
| 3 months | -25.17% | ||
| 6 months | -28.67% | ||
| Current year | -17.59% |
1 week
74.65
78.35
1 month
68.7078.35
Current year
68.70111.20
1 year
68.70111.20
3 years
46.66122.90
5 years
46.66122.90
10 years
41.40122.90
| Director | Title | Age | Since |
|---|---|---|---|
Dietmar Siemssen
CEO | Chief Executive Officer | 61 | 2018-10-31 |
Bernd Metzner
DFI | Director of Finance/CFO | 54 | 2019-05-14 |
Guido Pickert
IRC | Investor Relations Contact | - | - |
| Manager | Title | Age | Since |
|---|---|---|---|
Francesco Grioli
BRD | Director/Board Member | 52 | 2010-12-31 |
Axel Herberg
CHM | Chairman | 66 | 2015-04-29 |
Markus Rocholz
BRD | Director/Board Member | 54 | 2012-04-25 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 3.62% | 17 M€ | -.--% | - | |
| 2.97% | 202 M€ | -.--% | ||
| 0.25% | 18 M€ | +7.68% | ||
| 0.23% | 79 M€ | -.--% | ||
| 0.02% | 10 M€ | -3.35% | - |
| Change | 5d. change | 1-year change | 3-years change | Capi. ($) | ||
|---|---|---|---|---|---|---|
| +1.04% | +2.57% | -9.70% | -5.36% | 2.82B | ||
| +0.52% | -0.68% | +10.52% | -14.04% | 200B | ||
| -0.45% | -2.49% | +5.33% | -25.66% | 107B | ||
| -0.70% | +0.08% | -4.67% | -9.61% | 64.02B | ||
| -0.34% | +2.16% | +20.07% | +14.13% | 46.64B | ||
| -1.46% | -5.21% | +17.48% | +92.49% | 45.81B | ||
| +1.28% | -1.85% | -32.11% | -43.93% | 31.02B | ||
| +0.46% | -1.90% | +27.84% | +28.57% | 29.46B | ||
| -0.90% | -0.81% | -6.71% | -26.02% | 23.12B | ||
| -0.98% | -2.11% | -7.59% | -12.92% | 21.58B | ||
| Average | -0.28% | -1.19% | +2.04% | -0.24% | 57.2B | |
| Weighted average by Cap. | -0.11% | -1.69% | +6.28% | -4.72% |
| 2024 * | 2025 * | |
|---|---|---|
| Net sales | 2.05B 2.15B 1.9B 1.69B 3.04B 182B 3.37B 23.61B 8.71B 74.89B 8.07B 7.89B 327B | 2.34B 2.46B 2.17B 1.93B 3.48B 209B 3.86B 27.03B 9.98B 85.74B 9.24B 9.04B 374B |
| Net income | 127M 133M 117M 104M 188M 11.28B 209M 1.46B 539M 4.63B 499M 488M 20.21B | 166M 175M 154M 137M 248M 14.84B 274M 1.92B 709M 6.09B 656M 642M 26.59B |
| Net Debt | 1.01B 1.06B 933M 830M 1.5B 89.77B 1.66B 11.62B 4.29B 36.86B 3.97B 3.89B 161B | 983M 1.03B 911M 810M 1.46B 87.62B 1.62B 11.34B 4.19B 35.98B 3.88B 3.79B 157B |
More financial data
* Estimated data
Employees
12,012
Calendar
2024-12-10
- Drug Delivery to the Lungs Conference
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-12-11 | 76.50 € | -1.61% | 35,304 |
| 24-12-10 | 77.75 € | +1.04% | 90,657 |
| 24-12-09 | 76.95 € | +2.06% | 98,487 |
| 24-12-06 | 75.40 € | +0.53% | 80,020 |
| 24-12-05 | 75.00 € | -0.27% | 136,845 |
Delayed Quote Xetra, December 10, 2024 at 11:36 am EST
More quotes
Sell
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
77.75EUR
Average target price
113.57EUR
Spread / Average Target
+46.07%
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- GXI Stock